Donafenib + Tislelizumab

DRUG2 trials

Sponsors

Henan Cancer Hospital, Haibo Shao

Conditions

DiabetesHCC - Hepatocellular CarcinomaHepatocellular Carcinoma

Phase 2

Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence

Henan Cancer HospitalHepatocellular Carcinoma

Start: 2022-11-30End: 2024-11-30Target: 32Updated: 2022-09-19

Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes

Not yet recruitingNCT07557914

Haibo ShaoDiabetes, HCC - Hepatocellular Carcinoma

Start: 2026-06-01End: 2029-02-01Target: 32Updated: 2026-06-03